The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mLIt reduces viscosity by ...

The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces viscosity by up to 90% while maintaining formulation ...

WuXi Biologics introduces next-generation platform WuXiHigh2.0 for high-concentration biologics with protein concentration reaching 230 mg/mL: Shanghai Tuesday, July 1, 2025, 10:0 ...

The keen interest from Big Pharma has also excited the stock market. After the Otsuka deal was announced, HBM's share price ...

Law firms A&L Goodbody and Arthur Cox are the two big legal winners from continuing mergers and acquisitions activity linked ...

Introduction The global market for live biotherapeutic products and microbiome contract development and manufacturing organisations (CDMO) is u ...

Find insight on Samsung Biologics, China biotech companies and more in the latest Market Talks covering Health Care.

Review the current WuXi Biologics (Cayman) Inc (WXIBF:PINX) dividend yield and history to decide if WXIBF is the best investment for you.

The real-world evidence solutions market is largely driven by the increasing prevalence of chronic diseases and their impact on real-world healthcare ...

A high-level overview of WuXi Biologics (Cayman) Inc. (WXIBF) stock. View (WXIBF) real-time stock price, chart, news, analysis, analyst reviews and more.

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...